Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors

American Journal of Psychiatry

Volumn 174, Issue 10, 2017, Pages 927-942

  Leucht, Stefan ^a,b,c,d,e   Leucht, Claudia ^a,b,c,d,e   Huhn, Maximilian ^a,b,c,d,e   Chaimani, Anna ^a,b,c,d,e   Mavridis, Dimitris ^a,b,c,d,e   Helfer, Bartosz ^a,b,c,d,e   Samara, Myrto ^a,b,c,d,e   Rabaioli, Matteo ^a,b,c,d,e   Bächer, Susanne ^a,b,c,d,e   Cipriani, Andrea ^a,b,c,d,e   Geddes, John R ^a,b,c,d,e   Salanti, Georgia ^a,b,c,d,e   Davis, John M ^a,b,c,d,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b WARNEFORD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF BERN   (Switzerland)

^e MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ARIPIPRAZOLE; ASENAPINE; BREXPIPRAZOLE; CARIPRAZINE; CHLORPROMAZINE; HALOPERIDOL; ILOPERIDONE; LOXAPINE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PLACEBO EFFECT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QTC INTERVAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT GAIN; ADVERSE DRUG REACTION; BAYES THEOREM; MULTIVARIATE ANALYSIS; PATIENT DROPOUT; PSYCHOLOGY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA, PARANOID; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BAYES THEOREM; DEPRESSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MULTIVARIATE ANALYSIS; PATIENT DROPOUTS; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 85028536452     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.16121358     Document Type: Review

References (72)

1. Gøtzsche PC, Young AH, Crace J: Does long term use of psychiatric drugs cause more harm than good? BMJ 2015; 350:h2435
2. Moncrieff J: The Bitterest Pills: The Troubling Story of Antipsychotic Drugs. Basingstoke, UK, Palgrave McMillan, 2013
3. Angermeyer MC, VanderAuwera S, Matschinger H, et al: Thepublic debate on psychotropic medication and changes in attitudes 1990-2011. Eur Arch Psychiatry Clin Neurosci 2016; 266:165-172
4. Lacro JP, Dunn LB, Dolder CR, et al: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63:892-909
5. Lexchin J, Bero LA, Djulbegovic B, et al: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-1170
6. Heres S, Davis J, Maino K, et al: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163: 185-194
7. National Institute of Mental Health Psychopharmacology Service Center CollaborativeStudy Group: Phenothiazine treatment in acute schizophrenia: effectiveness. Arch Gen Psychiatry 1964; 10:246-261
8. Center for Drug Evaluation and Research: Application Number: 200603: Summary Review. Silver Spring, Md, Center for Drug Evaluation and Research, 2010. https://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/200603Orig1s000SumR.pdf
9. Agid O, Siu CO, Potkin SG, et al: Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry 2013; 170:1335-1344
10. Rutherford BR, Pott E, Tandler JM, et al: Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 2014; 71: 1409-1421
11. Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013; 382:951-962
12. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100
13. Carpenter WT Jr, Buchanan RW: Schizophrenia.NEngl JMed1994; 330:681-690
14. Leucht S, Tardy M, Komossa K, et al: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379:2063-2071
15. HonigfeldG: Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther 1984; 1:77-97
16. Gardner DM, Murphy AL, O'Donnell H, et al: International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693
17. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Chichester, UK, Wiley and Sons, 2011
18. McMahon RP, Kelly DL, Boggs DL, et al: Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr Bull 2008; 34:292-301
19. WuTX, Li YP, Liu GJ, et al: Investigation of authenticity of 'claimed' randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Abstracts of the 14th Cochrane Colloquium, Dublin, Ireland, 2006. https://abstracts.cochrane.org/2006-dublin/investigation-authenticity-claimed-randomizedcontrolled-trials-rcts-and-quality
20. Woodhead M: 80% of China's clinical trial data are fraudulent, investigation finds. BMJ 2016; 355:i5396
21. Adams CE, Coutinho E, Davis JM, et al: The Cochrane Library. Chichester, UK, John Wiley & Sons, 2011
22. Klein DF, Davis JM: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams and Wilkins, 1969
23. Adams CE, Awad G, Rathbone J, et al: Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007; 2: CD000284
24. Joy CB, Adams CE, Laurie S: Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 2006; 4:CD003082; update 2013; 11:CD003082
25. Shen X, Xia J, Adams CE: Flupenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev 2012; 11:CD009777
26. Matar HE, Almerie MQ: Oral fluphenazine versus placebo for schizophrenia. Cochrane Database Syst Rev 2007; (1):CD006352
27. Hartung B, Wada M, Laux G, et al: Perphenazine for schizophrenia. Cochrane Database Syst Rev 2005; (1):CD003443
28. Omori IM, Wang J: Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev 2009; (2):CD007811
29. Fenton M, Rathbone J, Reilly J, et al: Thioridazine for schizophrenia. Cochrane Database Syst Rev 2007; (3):CD001944
30. Leucht S, Arbter D, Engel RR, et al: How effective are secondgeneration antipsychotic drugs? A meta-analysis of placebocontrolled trials. Mol Psychiatry 2009; 14:429-447
31. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
32. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:790-812
33. Marshall M, Lockwood A, Bradley C, et al: Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry 2000; 176:249-252
34. Leucht S: Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry 2014; 75(suppl 1):8-14
35. Leucht S, Kane JM, Kissling W, et al: What does the PANSS mean? Schizophr Res 2005; 79:231-238
36. Schennach-Wolff R, Obermeier M, Seemüller F, et al: Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J Clin Psychopharmacol 2010; 30: 726-731
37. Furukawa TA, Barbui C, Cipriani A, et al: Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol 2006; 59:7-10
38. Salanti G, Higgins JP, White IR: Bayesian synthesis of epidemiological evidence with different combinations of exposure groups: application to a gene-gene-environment interaction. Stat Med 2006; 25:4147-4163
39. Samara MT, Cao H, Helfer B, et al: Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic reviewand metaanalysis challenging the dogma of equal efficacy of antipsychotic drugs. Eur Neuropsychopharmacol 2014; 24:1046-1055
40. Hartling L, Abou-Setta AM, Dursun S, et al: Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 2012; 157:498-511
41. Dold M, Samara MT, Li C, et al: Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev 2015; 1:CD009831
42. Higgins JPT, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560
43. Furukawa TA, Levine SZ, Tanaka S, et al: Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015; 72:14-21
44. Rabinowitz J, Werbeloff N, Caers I, et al: Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials. J Clin Psychiatry 2014; 75:e308-e316
45. Mallinckrodt CH, Zhang L, Prucka WR, et al: Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 2010; 43:53-72
46. George EI, McCuloch RE: Variable selection via Gibbs sampling. J Am Stat Assoc 1993; 88:881-889
47. Mattila T, Wohlfarth T, Koeter M, et al. Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia-an individual patient data meta-analysis. Eur Neuropsychopharmacol 2014; 24:1067-1077
48. Leucht S, Rothe P, Davis JM, et al: Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol 2013; 23: 956-959
49. Furukawa TA, Levine SZ, Tanaka S, et al: Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015; 72:14-21
50. Zohar J, Stahl S, Moller HJ, et al: A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 2015; 25:2318-2325
51. Schulz KF, Chalmers I, Hayes RJ, et al: Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-412
52. Wood L, Egger M, Gluud LL, et al: Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study.BMJ2008; 336: 601-605
53. Porta N, Bonet C, Cobo E: Discordance between reported intentionto-treat and per protocol analyses. J Clin Epidemiol 2007; 60: 663-669
54. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634
55. Peters JL, Sutton AJ, Jones DR, et al: Contour-enhanced metaanalysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 2008; 61:991-996
56. Mavridis D, Welton NJ, Sutton A, et al: A selection model for accounting for publication bias in a full network meta-analysis. Stat Med 2014; 33:5399-5412
57. Duval S, Tweedie R: Trimandfill: a simple funnel-plot-basedmethod of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455-463
58. Leucht S, Kane JM, Etschel E, et al: Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006; 31: 2318-2325
59. Leucht S, Kane JM, Kissling W, et al: Clinical implications of BPRS scores. Br J Psychiatry 2005; 187:363-371
60. Levine SZ, Rabinowitz J, Engel R, et al: Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 2008; 98:318-322
61. Cohen J: Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, New Jersey, Lawrence Erlbaum Associates, 1988
62. Leucht S, Busch R, Kissling W, et al: Early prediction of antipsychotic non-response among patients with schizophrenia. J Clin Psychiatry 2007; 68:352-360
63. Fusar-Poli P, Papanastasiou E, Stahl D, et al: Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull 2015; 41:892-899
64. Marder SR, Alphs L, Anghelescu IG, et al: Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res 2013; 150:328-333
65. Komossa K, Depping AM, Gaudchau A, et al: Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010; (12):CD008121
66. Trikalinos TA, Churchill R, Ferri M, et al: Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004; 57:1124-1130
67. Dechartres A, Trinquart L, Boutron I, et al: Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013; 346:f2304
68. Siu CO, Agid O, Remington G: Measuring the effects of treatment with antipsychotics. JAMA Psychiatry 2015; 72:514-515
69. Kemmler G, Hummer M, Widschwendter C, et al: Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005; 62:1305-1312
70. Tandon R, Fleischhacker WW: Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005; 79:145-155
71. Adelson D, Epstein LJ: A study of phenothiazines with male and female chronically ill schizophrenic patients. J Nerv Ment Dis 1962; 134:543-554
72. Casey JF, Bennett IF, Lindley CJ, et al: Drug therapy in schizophrenia: a controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo. Arch Gen Psychiatry 1960; 2:210-220